The Adva-27a Anti Cancer Compound is the big ticket here, and it looks like that is going from pre-clinical to clinical and thats why the insiders loaded big. Every other part of their business is just an added bonus building upon their generic pharmaceutical sales and service agreements with other biotechs.
News about an IND drug application accepted by the FDA will skyrocket $SBFM.
This is the quote from the latest 10Q
“Given the terminal and limited treatment options available for the Pancreatic Cancer, we anticipate being granted limited marketing approval (“compassionate-use”) for our Adva-27a following a successful Phase I clinical trial. It is likely that following such events, we will begin to receive offers from large pharmaceutical companies to buyout or license our drug. Alternatively, it may be more advisable for us to continue our own development of the drug by proceeding to Phase II clinical trials and attending to other requirements for full marketing approval.”
The funding will trigger the IND application.
And Now that “Right to Try” has passed in the USA, it’s all but guaranteed that Adva-27a will hit the market considering the terminal illness status of patients with pancreatic cancer.